Osteoarthritis (OA)
Osteoarthritis (OA) is among the most common chronic joint conditions, often marked by the breakdown of articular cartilage, thickening of the subchondral bone, and the formation of osteophytes. A key factor in OA is the reduced ability of chondrocytes—the cells responsible for maintaining cartilage—to generate enough functional matrix to repair damaged tissue.
While physical therapy, medications, and surgical interventions are widely discussed in managing OA symptoms such as pain, stiffness, and swelling, research indicates that these approaches primarily address symptom relief rather than halting the progression of the condition.
Studies conducted in the field of regenerative medicine have shown that Mesenchymal Stem Cells (MSCs) have the potential to support pain reduction and improvements in osteoarthritis symptoms. This effect is largely attributed to the unique differentiation capabilities of MSCs.
It is demonstrated that both TGF-β1 and insulin-like growth factor 1
(IGF-1) act synergistically to stimulate MSCs’ chondrogenic differentiation.
Mesenchymal stem cells (MSCs) derived from human umbilical cord blood (UCB) are often studied for their biological properties. Compared to MSCs from adipose tissue or bone marrow, UCB-MSCs are noted for characteristics such as higher proliferation rates, greater expansion potential, and relatively higher purity. Researchers also highlight the abundant availability of UCB-MSCs, making them a valuable focus of scientific studies.
Stem Cell Res Ther. 2020; 11: 492.
To Learn More :
